慢性気道感染性に対するｃｅｆｄｉｔｏｒｅｎ　ｐｉｖｏｘｉｌとｃｅｆｔｅｒａｍ　ｐｉｖｏｘｉｌの薬効比較試験成績

DOI

書誌事項

タイトル別名
  • Comparative clinical study of cefditoren pivoxil and cefteram pivoxil for chronic respiratory tract infections by a double-blind method.
公開日
1992
DOI
  • 10.11250/chemotherapy1953.40.1499
公開者
公益社団法人 日本化学療法学会

この論文をさがす

説明

A double-blind comparative study was carried out to determine the effficacy, safety and usefulness of cefditoren pivoxil (CDTR-PI), a new oral cephem, in the treatment of chronic respiratory tract infections, using cefteram pivoxil (CFTM-PI) as the reference drug. In principle, patients were treated by oral administration of either CDTR-PI or CFTM-PI at 200mg three times daily for 14 days. The following results were obtained.<BR>(1) The Clinical effficacy rate as judged by the committee was 85.9% (73/85) in the CDTR-PI group and 85.9% (67/78) in the CFTM-PI group, with no significant difference between the two treatment groups.<BR>(2) As to the bacteriological effifficacy as judged by the committee, the eradication rate was 84.2% (32/38) in the CDTR-PI group and 77.8% (28/36) in the CFTM-PI group. No significant difference was seen between the two treatment groups.<BR>(3) The incidence of side effects was 9.3% (9/97) in the CDTR-PI group and 6.3% (6/95) in the CFTM-PI group, and the incidence of abnormal laboratory findings 12.4% (11/89) and 11.5% (10/87), respectively, as judged by the committee. There was no significant differeance between the two groups.<BR>(4) The usefulness rate as judged by the committee was 80.2% (69/86) in the CDTR-PI group and 82.5% (66/80) in the CFTM-PI group, the difference not being significant.<BR>From these results it is concluded that CDTR-PI is an oral antibiotic with high usefulness in the treatment of chronic respiratory tract infections.

収録刊行物

キーワード

詳細情報 詳細情報について

  • CRID
    1390282681254607232
  • NII論文ID
    130004197712
  • DOI
    10.11250/chemotherapy1953.40.1499
  • ISSN
    18845894
    00093165
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ